Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$12.36

-0.63 (-4.85%)

, ICPT

Intercept

$83.79

-2.86 (-3.30%)

07:14
05/14/19
05/14
07:14
05/14/19
07:14

CymaBay initiated with a Buy at Citi

Citi analyst Joel Beatty started CymaBay Therapeutics (CBAY) with a Buy rating and $21 price target. The analyst believes the company's seladelpar will "likely dethrone" Intercept Pharmaceuticals' (ICPT) Ocaliva as the top-selling branded primary biliary cholangitis drug. Topline results for seladelpar in PBC are anticipated in 2021 and the analyst sees a 75% probability of approval.

CBAY

CymaBay

$12.36

-0.63 (-4.85%)

ICPT

Intercept

$83.79

-2.86 (-3.30%)

  • 18

    May

  • 12

    Jun

CBAY CymaBay
$12.36

-0.63 (-4.85%)

04/15/19
CANT
04/15/19
NO CHANGE
Target $20
CANT
Overweight
Genfit data show CymaBay may be differentiated, says Cantor Fitzgerald
Further competitor primary biliary cholangitis data from Genfit's (GNFTF) elafibranor suggest CymaBay Therapeutics' (CBAY) seladelpar may have a differentiated profile, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. The analyst keeps an Overweight rating on CymaBay with a $20 price target.
03/01/19
PIPR
03/01/19
NO CHANGE
Target $30
PIPR
Overweight
Piper Jaffray loves the setup for CymaBay shares into NASH data
CymaBay's Seladelpar has made "tremendous progress" in primary biliary cholangitis over the past year its competitive positioning continues to improve, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, the analyst believes the drug's nonalcoholic steatohepatitis opportunity is not currently being factored into the existing valuation. The analyst expects to receive topline data from the ongoing Phase IIb trial of seladelpar in NASH next quarter. If successful, it could "multiply" the $750M PBC opportunity in his model, Van Buren says in a research note titled "We Love The Setup Of CBAY Here; Reiterate The Overweight." He keeps a $30 price target on CymaBay shares.
02/22/19
LEER
02/22/19
INITIATION
Target $22
LEER
Outperform
CymaBay initiated with an Outperform at SVB Leerink
SVP Leerink analyst Pasha Sarraf initiated CymaBay with an Outperform rating and $22 price target, telling investors in a research note that the company is demonstrating "impressive" efficacy and safety profile in PBC and pre-clinically in NASH. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
02/20/19
PIPR
02/20/19
NO CHANGE
Target $30
PIPR
Overweight
'Underwhelming' Intercept data hurts CymaBay bear thesis, says Piper Jaffray
One of the major constituents of the CymaBay Therapeutics (CBAY) bear thesis has been that pricing for Intercept Pharmaceuticals' (ICPT) Ocaliva would get cut significantly with success in nonalcoholic steatohepatitis and consequently lower the eventual market opportunity for CymaBay's seladelapar in primary biliary cholangitis, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst, however, believes Intercept's Ocaliva data in NASH yesterday was "underwhelming" as the "fibrosis improvement was mild, no significant effect on NASH was observed, and worrisome safety and tolerability issues remain." Questions regarding the commercial viability of Ocaliva in NASH are now likely to persist, says Van Buren. He now believes Intercept will have to target the most severe patients, "significantly narrowing" the drug's addressable population. This should lead to more stable Ocaliva pricing than many currently assume and keep seladelpar's $750M-plus market opportunity in PBC "largely" intact, contends the analyst. Bottom line is that a major constituent of the CymaBay bear thesis has now been removed, he writes. Van Buren keeps an Overweight rating on the shares with a $30 price target. CymaBay Therapeutics closed yesterday up 34c to $10.29.
ICPT Intercept
$83.79

-2.86 (-3.30%)

05/13/19
WEDB
05/13/19
NO CHANGE
Target $243
WEDB
Outperform
Intercept price target lowered to $243 from $251 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Intercept to $243 from $251 following quarterly results and an update on the REVERSE trial of Ocaliva for the treatment of NASH cirrhosis. The analyst projects runway to cash flow positivity in Q1 of 2021, reiterates an Outperform rating on the shares and views recent weakness in the stock as a buying opportunity.
05/10/19
RILY
05/10/19
NO CHANGE
Target $158
RILY
Buy
Intercept added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani earlier today added Intercept Pharmaceuticals (ICPT) to his firm's Alpha Generator list. The analyst sees "strong" strong fundamentals over next year and a high likelihood of FDA approval in mid-2020. Mamtani lowered his price target for Intercept to $158 from $169 and keeps a Buy rating on the shares. His new target reflects the company's recent capital raise, the removal of removing Gilead (GILD) as near-term competitor with selonsertib's recent failure, and the push out of a European launch from the second half of 2020 to Q1 of 2021.
05/03/19
WELS
05/03/19
UPGRADE
Target $120
WELS
Outperform
Intercept upgraded to Outperform following survey of doctors at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Intercept to Outperform from Market Perform, stating that his recent survey of NASH prescribing doctors following the REGENERATE study update suggests a higher expected adoption rate of obeticholic acid and a more positive view of its efficacy. He also said he views the shares as oversold with Intercept down 12.5% year-to-date. Birchenough, who also cited recent NASH study failures of liver disease leader Gilead (GILD), raised his price target on Intercept shares to $120 from $104.
05/02/19
WELS
05/02/19
UPGRADE
WELS
Outperform
Intercept upgraded to Outperform from Market Perform at Wells Fargo

TODAY'S FREE FLY STORIES

06:45
05/27/19
05/27
06:45
05/27/19
06:45
General news
European stock marked moved broadly higher »

European stock marked…

05:50
05/27/19
05/27
05:50
05/27/19
05:50
General news
FX Update: Conditions have been thin »

FX Update: Conditions…

03:30
05/27/19
05/27
03:30
05/27/19
03:30
General news
FX Action: USD-CAD has settled in the mid 1.3400s »

FX Action: USD-CAD has…

03:00
05/27/19
05/27
03:00
05/27/19
03:00
General news
FX Update: Risk-off positioning have unwound some more in the forex markets »

FX Update: Risk-off…

02:35
05/27/19
05/27
02:35
05/27/19
02:35
General news
Asian Market Wrap: »

Asian Market Wrap:…

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.